Back to top

medical: Archive

Ekta Bagri

Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business?

Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor sentiment.

BIIBNegative Net Change BMYNegative Net Change LLYNegative Net Change

Zacks Equity Research

Can UNH's AI-Powered Virtual Assistance Enhance Member Experience?

UnitedHealth's AI-powered virtual assistants aim to simplify claims, boost engagement and deliver faster, more intuitive healthcare support.

UNHNegative Net Change HUMNegative Net Change ELVNegative Net Change

Zacks Equity Research

PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know

Praxis stock soars after late-stage data show strong efficacy for ulixacaltamide therapy in essential tremor and momentum builds toward an early-2026 regulatory filing.

ANIPNegative Net Change CRMDPositive Net Change ARQTNegative Net Change PRAXPositive Net Change

Zacks Equity Research

Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status

INCY secures FDA Breakthrough Therapy status for INCA033989 after early data show rapid and sustained platelet normalization in essential thrombocythemia patients.

INCYNegative Net Change ANIPNegative Net Change CRMDPositive Net Change ARQTNegative Net Change

Zacks Equity Research

CONMED Stock Falls as It Strategically Exits Gastroenterology Portfolio

CNMD is set to exit its gastroenterology portfolio to streamline its focus on higher-growth surgical platforms and boost long-term margins.

BSXNegative Net Change CNMDPositive Net Change ISRGNegative Net Change MEDPPositive Net Change

Urmimala Biswas

Tempus AI: Data Flywheel and MRD Expansion Reshape the Outlook

Tempus AI's data engine, MRD buildout and ADLT milestones set the stage for faster growth while profitability metrics turn the corner.

ILMNNegative Net Change GHPositive Net Change TEMPositive Net Change

Swayta Shah

Bet on These 3 Stocks With Upgraded Broker Ratings Amid Uncertainties

Illumina, Commercial Metals and Newmont have all seen broker upgrades, signaling bullish momentum amid market uncertainties.

ILMNNegative Net Change NEMNegative Net Change CMCNegative Net Change

Moumi Mondal

HOLX Stock Up 16% in 6 Months: Is it Still a Hold Heading Into 2026?

Hologic shares rise 16% in six months, with divisional strength clinical data and a go-private deal shaping the short-term outlook.

ABTNegative Net Change HOLXNegative Net Change QGENNegative Net Change

Sundeep Ganoria

3 Generic Drug Stocks to Watch Amid Changing U.S. Landscape

Generic drugmakers face U.S. pricing pressure, but TEVA, SDZNY and RDY gain momentum through complex generics and biosimilars.

RDYNegative Net Change TEVANegative Net Change SDZNYPositive Net Change

Abhinab Dasgupta

Beat the Market the Zacks Way: Veracyte, Las Vegas Sands, 3M in Focus

Veracyte, Las Vegas Sands and 3M shine as Zacks spotlights standout stock gains and portfolio wins amid shifting market sentiment.

KOPositive Net Change AMGNNegative Net Change MMMNegative Net Change MUPositive Net Change TMONegative Net Change LRCXPositive Net Change LVSPositive Net Change AUNegative Net Change FOLDNegative Net Change MTZPositive Net Change VCYTNegative Net Change

Indrajit Bandyopadhyay

ISRG Stock Forms Golden Crossover: Will the Uptrend Continue?

Intuitive Surgical's golden crossover arrives amid surging procedures and rapid dV5 adoption, raising the stakes for its bullish momentum.

MDTNegative Net Change SYKNegative Net Change ISRGNegative Net Change

Zacks Equity Research

PODD Stock Benefits From FDA Approval of Omnipod 5's Enhancements

Insulet Stock rises as the FDA clears key Omnipod 5 upgrades that enhance glucose targets and automation for its tubeless diabetes platform.

OMCLPositive Net Change ILMNNegative Net Change PODDNegative Net Change BTSGNegative Net Change

Zacks Equity Research

Best Value Stocks to Buy for December 8th

GM, CRMD and AER made it to the Zacks Rank #1 (Strong Buy) value stocks list on December 8, 2025.

GMNegative Net Change AERNegative Net Change CRMDPositive Net Change

Zacks Equity Research

New Strong Sell Stocks for December 8th

AKR, AVTR and CRI have been added to the Zacks Rank #5 (Strong Sell) List on December 8, 2025.

AKRNegative Net Change CRINegative Net Change AVTRNegative Net Change

Zacks Equity Research

New Strong Buy Stocks for December 8th

VFF, CRMD, AER, GM and FIVE have been added to the Zacks Rank #1 (Strong Buy) List on December 8, 2025.

GMNegative Net Change FIVEPositive Net Change AERNegative Net Change CRMDPositive Net Change VFFNegative Net Change

Zacks Equity Research

BD Stock Up Post Tie-Up to Expand Hazardous Drug Contamination Testing

BDX teams up with ChemoGLO to expand hazardous drug testing, aiming to boost safety in healthcare environments.

BDXNegative Net Change ISRGNegative Net Change CAHPositive Net Change SOLVNegative Net Change

Zacks Equity Research

GEHC Forms 7-Year Care Alliance to Advance URMC Imaging & Monitoring

GE HealthCare's seven-year alliance with URMC advances imaging, precision medicine and system-wide monitoring upgrades across UR Medicine.

BSXNegative Net Change ISRGNegative Net Change MEDPPositive Net Change GEHCNegative Net Change

Zacks Equity Research

ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study

Absci Corporation stock jumps after initiating dosing in its phase I/IIa ABS-201 study for androgenetic alopecia, seeking early safety and efficacy signals.

ANIPNegative Net Change CRMDPositive Net Change ARQTNegative Net Change ABSINegative Net Change

Zacks Equity Research

CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know

Capricor Therapeutics stock soars after meeting key goals with statistical significance in a phase III study of deramiocel for Duchenne cardiomyopathy.

ANIPNegative Net Change CRMDPositive Net Change CAPRPositive Net Change ARQTNegative Net Change

Ekta Bagri

Denali Enters Into a $275M Funding Deal With Royalty Pharma

DNLI secures a $275M funding deal with Royalty Pharma tied to potential approvals for its Hunter syndrome therapy.

BIIBNegative Net Change RPRXNegative Net Change DNLINegative Net Change TAKPositive Net Change

Vasundhara Sawalka

4 Stocks Trading Near 52-Week High With Room to Rise Further

Investors target stocks that have been on a bullish run. Stocks like KSS, HRTG, MD and NEM are seeing price strength, and the momentum is likely to continue.

KSSNegative Net Change NEMNegative Net Change MDNegative Net Change HRTGPositive Net Change

Ekta Bagri

Will Breyanzi's Label Expansion Boost BMY's CAR T Cell Therapy Sales?

Bristol Myers gains FDA approval to expand Breyanzi's label to R/R marginal zone lymphoma, strengthening its CAR T portfolio amid rising sales.

NVSNegative Net Change BMYNegative Net Change GILDNegative Net Change

Urmimala Biswas

Tempus AI: Revenue Mix and 2026 Growth Outlook Explained

Tempus AI's balanced genomics and data engine is scaling fast as profitability metrics improve and 2026 revenue targets approach the billion-plus mark.

EXASNegative Net Change GHPositive Net Change TEMPositive Net Change

Zacks Equity Research

COO Gains as Q4 Earnings & Sales Beat Estimates, MyDay Adoption Rises

COO jumps after Q4 earnings and sales top estimates, powered by rising MyDay demand and strong MiSight momentum.

ISRGNegative Net Change COONegative Net Change MEDPPositive Net Change SGHTPositive Net Change

Zacks Equity Research

Here's Why You Should Add Inogen Stock to Your Portfolio Now

INGN gains momentum from rising POC demand, new product launches and strong Q3 sales, even as competition and forex swings temper near-term growth.

ISRGNegative Net Change INGNNegative Net Change MEDPPositive Net Change SGHTPositive Net Change